Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Spero Therapeutics Q3 EPS $(0.06) Misses $(0.03) Estimate, Sales $25.47M Beat $14.97M Estimate

Author: Benzinga Newsdesk | November 13, 2023 05:19pm
Spero Therapeutics (NASDAQ:SPRO) reported quarterly losses of $(0.06) per share which missed the analyst consensus estimate of $(0.03) by 100 percent. This is a 81.82 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $25.47 million which beat the analyst consensus estimate of $14.97 million by 70.16 percent. This is a 1.17K percent increase over sales of $2.01 million the same period last year.

Posted In: SPRO


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist